Adherex completes acquisition of Cadherin Biomedical
Continue reading below...
ExplainersWhy does immunotherapy work better for some cancers than others?
A powerful tool in modern oncology, immunotherapy doesn’t work the same for everyone. Researchers are exploring why and developing ways to improve its effectiveness.
Read MoreRESEARCH TRIANGLE PARK, N.C.—Adherex Technologies Inc., announced in early December the completion of its acquisition of Cadherin Biomedical Inc. (CBI).
"This acquisition brings back to Adherex's portfolio the non-cancer applications of our cadherin platform," says Dr. William Peters, chairman and CEO. "While Adherex will continue to focus on advancing our oncology drugs through clinical development, these non-cancer assets will likely be of interest to potential partners and the completion of this acquisition should strengthen our negotiating position."
Under the terms of the buyout, Adherex issued approximately 3.2 million shares of Adherex common stock to CBI shareholders in exchange for all of the issued and outstanding shares of CBI.
Albany Molecular Research announces drug discovery collaboration with Alcon
ALBANY, N.Y.—Albany Molecular Research Inc. announced in early January that it has entered into a two-year research collaboration with Alcon Research Ltd. to discover and develop ophthalmic pharmaceuticals.
Under the terms of the agreement, AMRI will screen samples from its natural product collections, with the goal of identifying and developing lead compounds with desired biological activity against ophthalmic-related biological targets. AMRI will also provide custom chemical synthesis services.
Continue reading below...
Ebooks Advancing cell therapies with smarter strategies
Researchers are finding creative ways to make cell therapies safer and more effective.
Read More"We are looking forward to the opportunity to work with Alcon, the world's leading ophthalmic company, to help it discover and develop novel therapeutic compounds for eye diseases," says AMRI Chairman, president and CEO Thomas E. D'Ambra, Ph.D. "We are particularly excited about the opportunity to screen our purified natural products collections in this drug discovery collaboration."
MDS Pharma Services names VP of global marketing
MONTREAL—MDS Pharma Services, a provider of drug discovery and development solutions, has appointed Robert D. Lefebvre vice president of global marketing. In his role, Lefebvre is responsible for all marketing strategy and implementation for the organization.
